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Florfenicol, which is licensed for veterinary use only, proves to be a potent antimicrobial
for treatment of respiratory disease. However, the subsequent exposure of the gut
microbiota to florfenicol is not well described. Hence, the effect of various administration
protocols on both plasma and gastro-intestinal florfenicol concentrations in pigs was
evaluated. In field situations were simulated by application of different administration
routes and dosages [single oral bolus at 10 or 5 mg/kg body weight (BW), medicated
feed at 10 or 5 mg/kg BW and intramuscular injections at 15 or 30 mg/kg BW]. After
intramuscular administration of 30 mg florfenicol/kg BW, gastro-intestinal concentrations
of florfenicol, quantified 10 h after the last administration, were significantly elevated in
comparison with the other treatment groups and ranging between 31.5 and 285.8 µg/g
over the different gut segments. For the other treatment groups, the influence of
dose and administration route was not significantly different. Bacteriological analysis
of the fecal samples from the animals at the start of the experiment, demonstrated
the presence of both florfenicol susceptible (with minimal inhibitory concentration (MIC)
values of 2–16 µg/mL) and florfenicol resistant (MIC ≥ 256 µg/mL) Escherichia coli
isolates in all treatment groups. Following, at 10 h after the last administration the
susceptible E. coli population was eradicated in all treatment groups due to the high
intestinal florfenicol concentrations measured. Moreover, selection of the resistant E. coli
strains during treatment occurred in all groups. This is likely related to the fact that
the different treatment strategies led to high gastro-intestinal concentrations albeit
not reaching the high magnitude of MIC values associated with florfenicol resistance
(≥256 µg/mL). Conclusively, in our experimental setup the administration route and
dose alterations studied, had no influence on monitored florfenicol resistance selection
in E. coli from the microbiota.
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INTRODUCTION
Antimicrobial resistance in bacteria is a constantly evolving
phenomenon, with the extent of resistance increasing in parallel
with the use of antimicrobials on a population level. The
dissemination of antimicrobial resistance harbors the threat
of compromising therapeutic efficacy in battling bacterial
infections. Constraining these resistance issues is a crucial
objective in human as well as in veterinary medicine. Current
marketed antimicrobials are optimized solely based on their
clinical efficacy, focussing on the target pathogen, without taking
resistance selection in the commensal, non-target, microbiota
into account. For instance, the intestinal microbiota (Liu et al.,
2002). However, resistance in the microbiota poses a significant
threat and concern for the spread of resistance in animals and
also humans, according to the One Health approach (European
Commission[EC], 2018). Hence, investigating the influence of
the posology of antimicrobial therapy on selection of resistance
in the commensal gut microbiota is an important strategy.
Florfenicol (FF), a derivate of chloramphenicol (CAP), is
a broad-spectrum antimicrobial exclusively used in veterinary
medicine. CAP has been banned for many years in food-
producing animals, and is generally not used in human medicine
because of its potential adverse effects such as aplastic anemia
(Skolimowski et al., 1983). Thiamphenicol (TIA), another
derivate, is available for parenteral use in case of severe infections
(BCFI, 2018). Nonetheless, FF is safely applied in multiple
animal species, such as swine, for respiratory tract infections.
It exerts bacteriostatic activity against several bacterial species
associated with porcine respiratory tract disease, including
Actinobacillus pleuropneumoniae and Pasteurella multocida
(Dorey et al., 2016). Acquired resistance to FF is generally
very low or absent for these respiratory tract pathogens (Vanni
et al., 2012). Apart from these target pathogens, the gut
microbiota could also be exposed to FF during treatment. In
general, FF has bacteriostatic activity against Enterobacteriaceae
such as Escherichia coli and Salmonella Typhimurium, though
often with elevated minimal inhibitory concentration (MIC)
values (Syriopoulou et al., 1981). Several plasmids carrying FF
resistance genes have already been associated with acquired
FF resistance in E. coli isolates obtained from pigs (Blickwede
and Schwarz, 2004) and cattle (Singer et al., 2004). Hence,
antimicrobial therapy with FF could select for resistant
E. coli, populations residing in the microbiota. Acrangioli
et al. (2000) reported that all FF resistant isolates monitored,
harbored floR resistance genes, conferring for an eﬄux protein
belonging to the major facilitator (MF) superfamily of drug
exporters (Braibant et al., 2005). Furthermore these isolates also
displayed multiple drug resistance conferring to the ACSSuT
(ampicillin, chloramphenicol, streptomycin, sulphonamides, and
tetracyclines) genotype. Hence, FF induced selection of multi-
drug resistant strains in the gut microbiota could pose a
significant risk in terms of multi-drug resistance spread (Mather
et al., 2013). Resistance to FF is not mediated by CAP
resistance determinants, such as the enzyme chloramphenicol
acetyltransferase (CAT) or the gene cmlA (Singer et al., 2004).
However, these resistance determinants are also linked to
mobile genetic elements; hence co-selection of CAT resistance
by use of FF is also possible (Blickwede and Schwarz,
2004).
In order to assess the effects of an antimicrobial treatment
on the microbiota, intestinal concentration data could provide
valuable insights, which are lacking for many molecules in
the current literature. For instance data on FF intestinal
concentrations and subsequent microbiota exposure, during
conventional treatment strategies in pigs, are not publicly
available. In general, parenteral administration allows for more
accurate dosing. Furthermore, it is assumed that a parenteral
administration will lead to less gastro-intestinal exposure of the
microbiota, because no absorption from the gut is required.
This is in contrast with oral administration of antimicrobials.
Nevertheless, De Smet et al. (2017) recently reported that
similar gut concentrations of sulfadiazine and trimethoprim
were obtained in pigs after oral and parental treatment. The
same observation was reported by Devreese et al. (2014) after
administering different doses of enrofloxacin in broilers via oral
or parenteral route.
The present study investigated the gastro-intestinal
concentrations of FF in different gut segments after administering
the antimicrobial through oral gavage (not used in-field) and via
medicated feed or intramuscular (IM) injection to simulate the
actual in-field situation (Callens et al., 2012). Different dosage
schemes were administered to assess the possible dose-related
pharmacokinetic (PK) properties of FF. Subsequently; the fecal
samples from the same animals were also used to study the
selective effect for FF resistance in E. coli, as a Gram-negative
indicator bacterium for the intestinal microbiota.
MATERIALS AND METHODS
Animal Experiment
The animal experiment was approved by the Ethical Committee
of the Faculties of Veterinary Medicine and Bioscience
Engineering of Ghent University (case number EC 2015-16). The
experiment was conducted with 36 pigs (Topigs 20, 12 weeks
old, mixed genders) randomly divided into six FF treatment
groups, each with a specific dosing scheme (Table 1). The animals
were group-housed (n = 3) in separate confinements, within
the same stable, on 50/50 concrete floor/grids. Before the start
of the experiment all animals were allowed an acclimatization
period of 5 days. For administration through oral gavage
(groups 1 and 2), Amphen R© oral granulated powder was used
(Huvepharma NV, Antwerpen, Belgium). Groups 1 and 2 were
administered an individually calculated single bolus, based on
bodyweight (BW), of 5 mg FF/kg BW and 10 mg FF/kg BW,
respectively, for 5 consecutive days. For the IM administrations
(groups 3 and 4), Colfen R© (Zoetis, Zaventem, Belgium) was
administered twice in total, with a 48-h-interval, as described
by the manufacturer at doses of 15 mg FF/kg BW and 30 mg
FF/kg BW, respectively. The injection site was located in the
neck, behind the base of the ear. In groups 5 and 6, FF was
administered via medicated feed based on the average group
BWs (per confinement of 3 animals). For these administrations,
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TABLE 1 | Overview of the different treatment groups with mean bodyweight (BW), for the animal experiment.
Group Administration route Dosing scheme Mean BW ± SD (kg)
1 PO (oral gavage) Half dose: 5 mg FF/kg BW 28.8 ± 5.5
Once daily, 5 days
2 PO (oral gavage) Conventional: 10 mg FF /kg BW 29.8 ± 4.5
Once daily, 5 days
3 IM (intramuscular injection) Conventional: 15 mg FF/kg BW 34.6 ± 5.8
2 injections, 48 h interval
4 IM (intramuscular injection) Double dose: 30 mg FF/kg BW 35.9 ± 5.8
2 injections, 48 h interval
5 PO (medicated feed) Half dose: 5 mg FF/kg BW 30.1 ± 4.7
Once daily, 5 days
6 PO (medicated feed) Conventional: 10 mg FF/kg BW 31.4 ± 3.0
Once daily, 5 days
The animals were 12 weeks old, mixed genders and were group-housed (n = 3 per confinement) on 50/50 concrete floor/grids.
Floron R© premix (KRKA Belgium NV, Sint-Niklaas, Belgium) was
mixed into feed at an under dosage of 5 mg FF/kg BW and at
conventional doses of 10 mg FF/kg BW, respectively for groups
5 and 6, again for 5 consecutive days. The animals received the
complete amount of medicated feed in one administration at
a fixed time point; allowing feed uptake during several hours.
However, no ad libitum access to medicated feed was allowed, in
order to estimate feed intake correctly. Blood samples (±1 mL)
were collected in all treatment groups (n = 36) in heparin-
containing vacuum tubes (Vacutest Kima, Arzergrande, Italy),
through venepuncture (vena jugularis) at different time points
(0.5, 1, 2, 3, 4, 6, 8, and 10 h) after the first administration
of FF in each group. At time point 0 h and 10 h after the
first administration, fecal samples were also collected in all
treatment groups (n = 36) via rectal stimulation. Plastic sterile
cups (40 mL) were filled, but contents were not quantified
during collection. For the remaining treatment days, blood was
collected at fixed time points, corresponding with the estimated
time at maximal plasma concentrations (Tmax) of 2 h post-
administration in all treatment groups (n = 36). Furthermore,
blood was also collected every 10 h post-administration and
also prior to the next FF administration in all treatment
groups (n = 36). Fecal samples were collected (via rectal
stimulation) twice daily, pre- and 10 h post-administration of
FF in all treatment groups (n = 36) during the remainder of the
experiment.
On day three and five after initiating treatment, the animals
of the IM and oral groups, respectively were euthanized, at
10 h after the last administration. Euthanasia was exerted with
an intra-cardiac injection of sodium pentobarbital 20% (Kela
Veterinaria, Sint-Niklaas, Belgium) after anaesthesia with a mix
of 0.3 mg/kg BW xylazine (Xyl-M R©, V.M.D. Vet, Arendonk,
Belgium) and 15 mg/kg BW tiletamine-zolazepam (Zoletil 100 R©,
Vibrac, Barneveld, Netherlands). Intestinal contents (luminal)
were collected from different gut segments (duodenum, mid-
jejunum, ileum, cecum, mid-colon, and rectum). The contents
were sampled in a qualitative manner by use of sterile plastic
beakers, and each sample was weighed. All blood samples were
centrifuged (2851 × g, 10 min, 4◦C) and plasma was collected
and stored at ≤ −15◦C for a maximum of 8 weeks until
analysis for FF concentration. All fecal samples and intestinal
contents were lyophilised for 48 h consecutively and weighed
again afterward, and were manually grounded homogenously and
stored at≤−80◦C for a maximum of 20 weeks until quantitative
and bacteriological analysis.
Analysis of Florfenicol in Plasma and
Intestinal Content
Chemicals and Reagents
Analytical grade Ultra Performance Liquid Chromatography
(UPLC) solvents were used: acetonitrile (ACN), methanol
(MeOH) and water (H2O) from Fisher Scientific (Erembodegem,
Belgium), ethyl acetate and glacial acetic acid from VWR
(Leuven, Belgium). The analytical standard of FF and internal
standard thiamphenicol (TIA) were purchased from Sigma-
Aldrich (Diegem, Belgium). Standard stock solutions of
1.0 mg/mL were prepared in a H2O/MeOH solution (50/50 v/v)
and were stored airtight and protected from light at 4–8◦C for a
maximal period of 3 weeks. Phosphate-buffered saline (PBS) was
obtained from Sigma-Aldrich (Diegem), and sodium hydroxide
(NaOH) from VWR (Leuven).
Sample Preparation
The fecal and intestinal samples were lyophilised. The loss-on-
drying from each sample was compensated for based on the
weights of the samples pre -and post lyophilisation, determined
by use of an analytical balance. These samples were then weighed
for quantitative analysis (1.0 g) and diluted 10-fold in PBS.
Following, sample treatment for fecal and plasma samples was
based on liquid-liquid extraction (LLE). Briefly, 25.0 µL of the
internal standard solution (TIA, 100.0 µg/mL) and 100.0 µL of
a 1M NaOH solution (pH 9 for optimal extraction yield) were
added to each of the fecal and intestinal samples. Next, LLE
was performed by adding 6 mL ethyl acetate. After roller-mixing
(10 min) and centrifugation (2851 × g, 10 min), the supernatant
was separated and dried under nitrogen flow (40 ± 2◦C). The
extract was reconstituted using 500.0µL of a 90/10 v/v H2O/ACN
solution. Processing of plasma samples was very similar; 25.0 µL
of the internal standard (TIA, 50.0 µg/mL) and 25.0 µL of a 1M
NaOH solution were added to the plasma aliquot of 250 µL, 3 mL
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ethyl acetate was used for extraction. Reconstitution was achieved
with 250.0 µL of a 90/10 v/v H2O/ACN solution.
UPLC-PDA Analysis
Liquid chromatography was performed on an Acquity UPLC
H-Class system (Waters NV, Zellik, Belgium). Chromatographic
separation was achieved using an Acquity UPLC C18 column
(2.1 mm× 50 mm, d.p.: 1.7 µm) in combination with an Acquity
UPLC VanGuard pre-column (2.1 mm × 5 mm, d.p.: 1.7 µm),
both obtained from Waters NV (Zellik, Belgium). Column oven
temperature was 45.0◦C and the autosampler tray was kept at
8.0◦C. Mobile phases for chromatographic separation consisted
of 0.1% glacial acetic acid in H2O (A) and ACN (B). The following
gradient elution program was applied: 0–3.75 min (90% A, 10%
B), 3.75–5.5 min (linear gradient to 40% A, 60% B), 5.5–6.0 min
(linear gradient to 5% A, 95% B), 6.0–8.0 min (5% A, 95% B), 8.0–
8.30 min (linear gradient to 85% A, 15% B), 8.30–11.00 min (90%
A, 10% B). Flow rate was 400 µL/min. For detection, an Acquity
UPLC Photo Diode Array (PDA) detector (Waters NV, Zellik,
Belgium) was used. System parameters for Ultra-Violet (UV)
detection were optimized using working solutions, i.e., 0.1µg/mL
FF, and the internal standard TIA, in a H2O/ACN mixture
(90/10 v/v). For the quantification of FF, a wavelength of 223 nm
was selected for maximal absorbance, after measuring a full
spectrum. The analytical method was validated based on different
parameters (precision, accuracy, limit of detection (LOD), limit
of quantification (LOQ), and goodness-of-fit) using matrix-
matched calibrator and quality control samples. Validation was
exerted according to De Baere et al. (2012).
Pharmacokinetic Analysis
Phoenix R© WinNonlin R© 6.3 (Pharsight-Certara, Princeton, NJ,
United States) was used for the pharmacokinetic (PK) analysis
of the data via non-compartmental modelling (NCA). The area
under the curve (AUC) was calculated using the linear up-log
down trapezoidal method. Furthermore, several PK parameters
were calculated: area under the 24 h-time curve (AUC0−24 h),
area under the 58 h- or 106 h-time-curve (AUC0−58 h or
AUC0−106 h). The AUC0−58 h or AUC0−106 h values were
also normalized for dosage administered by dividing these
values with the actual dosage (µg) administered per animal:
AUC0−58 h/D or AUC0−106 h/D. The maximal plasma or fecal
concentrations Cmax and time of maximal concentration Tmax
were also calculated by NCA.
Enumeration, Identification and
Characterization of E. coli in Fecal
Samples
The fecal samples collected at time point 0 h before treatment
and at 10 h after the last treatment (58 h for IM groups, 106 h
for oral groups) were used for enumeration of E. coli. For
these analyses, samples of three pigs were randomly selected
from each treatment group for testing. The freeze-dried samples
were weighed (1 g), reconstituted and serially 10-fold diluted
(weight-based) in sterile PBS. Next, a spiral plater (IUL S.A.,
Barcelona, Spain) was used for plating 40 µL of each dilution
onto (i) McConkey agar n◦3 (MC; Oxoid NV, Erembodegem,
Belgium) and (ii) MC agar supplemented with 16 µg/mL FF
(EUCAST ECOFF value of E. coli for FF). After drying for a
few minutes, the agar plates were aerobically incubated at 37◦C
for at least 20 h before performing a total plate count, on the
dilution with a colony density of 20–300 per plate (Sutton, 2011).
Per plate up to 3 different, large and regular shaped lactose
positive colonies were purified and identified by Matrix-Assisted
Laser Desorption Ionization-Time-Of-Flight Mass Spectrometry
(MALDI-TOF MS, Bruker Daltonik, Evere, Belgium). For this
analysis, purified colonies were applied to the MALDI target plate
and covered with the appropriate matrix (1 µL of α-cyano-4-
hydroxycinnamic acid) as instructed by Bruker Daltonik. MBT
Compass software 4.1 (Bruker Daltonik, Evere)) was used for
obtaining spectra which were matched against a database of 6.120
mean spectra projections (MSP). Only score values of ≥2.000
were taken into account.
Repetitive element sequenced-based (rep)-PCR was used for
determination of genetic diversity among the different collected
E. coli isolates. The protocols and materials used were similar to
Peeters et al. (2018).
Statistical Analysis
Statistical analysis was performed by using SPSS 25.0 (IBM,
Chicago, IL, United States). Plasma or intestinal concentrations
and water content results were compared between the groups
by means of a single-factor analysis of variance (ANOVA) under
the assumption of normality and equal variances (Levene’s test).
For post-hoc testing either Tukey was selected or Games-Howell
in case of non-equal variances, in either case the significance
level α was set at p = 0.05. All data are represented as
mean± SD, with n indicating the number of observations, unless
otherwise indicated. Mean + SD is displayed for the graphical
representation of the data.
RESULTS AND DISCUSSION
Analytical Method Validation
The validation results for the different parameters are presented
in Supplementary Tables A, B. The limit of quantification
(LOQ) for FF was 0.125 µg/g in feces and 0.100 µg/mL
in plasma. All parameters fulfilled the validation criteria as
described in the Supplementary Tables A,B and as given by the
De Baere et al. (2012), the Veterinary International Conference
of Harmonisation (VICH) guidelines (VICH, 2015) and the
European Commission (EC) guidelines on the performance of
analytical methods (Kehrenberg et al., 2004).
Animal Experiment
During treatment with FF all animals presented a known
treatment side-effect, namely diarrhea. For most animals this
occurred during the second day of treatment and lasted for the
entire treatment period. However, all animals were found to be
clinically healthy during the entire treatment period. No control
data is available to compare the extent of diarrhea with untreated
animals.
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FIGURE 1 | (A) Plasma concentrations of florfenicol (FF) after the first administration (0–24 h) and during entire treatment period (0–106 h) with bolus administration
of 5 mg FF/kg BW in group 1 and 10 mg FF/kg BW in group 2. The bolus was administered once daily for 5 consecutive days. (B) Plasma concentrations of FF after
the first administration (0–24 h) and during entire treatment period (0–58 h) with FF administered IM twice, with a 48 h-intervals in group 3 (15 mg FF/kg BW) and 4
(30 mg FF/kg BW). (C) Plasma concentrations of FF during entire treatment period (0–106 h) with medicated feed administered once daily at dosages of 5 mg FF/kg
BW in group 5 and 10 mg FF/kg BW in group 6, for 5 consecutive days. All results are represented as mean + SD (n = 6).
Plasma FF Concentrations
The average plasma concentrations + standard deviation (SD)
after FF administration are displayed in Figure 1A for treatment
groups 1, 2 and Figure 1B for treatment groups 3, 4, up
to 10 h after the first administration and during the full
treatment period (106 h oral groups 1, 2, and 58 h for the
IM groups 3, 4). Blood sampling is displayed in Figure 1C
for the groups receiving medicated feed (5 and 6), during
the full treatment period (106 h). The plasma PK parameters
that were calculated for the different treatment groups are
shown in Table 2. These parameters for FF in plasma are in
agreement with other literature reports for IM administration
(Dorey et al., 2017) and in-feed mixing of FF (Jiang et al.,
2006).
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Similar plasma concentrations were reached over a 24-h-
timespan after the oral bolus administration of FF and the
IM administration for groups 1 and 3, respectively in this
study, despite the lower oral dosage. These findings are also in
accordance with a study by Liu et al.(2003) indicating high oral
bioavailability, in the range of 100%, of FF in pigs. Thus in
spite of its low solubility in water, oral administration of FF can
lead to high systemic availability. Moreover, lower Cmax values
were observed after IM administration in comparison with an
oral bolus administration, which is likely due to a depot effect
occurring in the muscle tissue and thus causing a prolonged slow
release from the injection site, as also reported by Voorspoels
et al. (1999) and Lobell et al (1994). The impact of in-feed
mixing of FF on the oral bioavailability was also investigated
by comparison of the AUC0−106 h values between the groups
receiving oral bolus (1,2) and medicated feed (5,6) with the same
respective dosages. No statistical significant differences (p< 0.05)
were detected between group 1 and 5 (p = 0.91) and group 2 and 6
(p = 0.30). Hence, the plasma concentrations of FF during the 5-
day treatment period are not statistically different after oral bolus
or medicated feed administration, for a given dose. Finally, the
relation between dose and plasma concentration was linear. After
normalizing the AUC0−end values with the dose administered (in
µg) for the sets of groups 1–2, 3–4, and 5–6, constant values
between these sets of groups were achieved (Table 2). Hence,
doubling or halving the dose of FF for the same administration
route, will have a similar impact on systemic exposure to FF.
Intestinal and Fecal FF Concentrations
After lyophilisation of the intestinal and fecal samples, the loss
of water content was calculated. Subsequently, the determined FF
concentrations from the lyophilised material were compensated
for based on the water loss from each individual sample. Hence,
the FF concentrations as given throughout the manuscript are
based on the weight of the actual samples, taking water content
into account.
The intestinal concentrations in the different gastro-intestinal
segments were compared over the different treatment groups
(Table 3). Group 4, administered the highest dose of 30 mg FF/kg
BW via IM injection, showed significantly higher (p < 0.05) FF
concentrations in most of the gastro-intestinal segments (apart
from ileum and colon) in comparison with the other groups.
Group 6, administered medicated feed at 10 mg FF/kg BW,
showed significantly higher jejunal concentrations in comparison
with the other groups (apart from group 4). This is most probably
related to the ongoing uptake of FF in the proximal segments,
after medicated feed administration. The high FF concentrations
established after IM administration are likely related to a
mechanism of enterohepatic recirculation (Liu et al., 2003)
and/ or a gastro-intestinal secretion from blood to gut lumen
(De Smet et al., 2017), consequently these processes can also
occur after oral administration of FF. However, neither of these
mechanisms has been elucidated for FF in pigs. Furthermore,
no significant differences were detected when comparing the
intestinal concentrations between the other treatment groups
over the different gastro-intestinal segments. These data suggest
that the administration route has no effect on FF exposure in
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TABLE 3 | Intestinal content concentrations of florfenicol (FF) in the different gastro-intestinal segments.
Mean Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
concentration Bolus Bolus IM IM Feed Feed
(µg/g) 5 mg FF/kg BW 10 mg FF/kg BW 15 mg FF/kg BW 30 mg FF/kg BW 5 mg FF/kg BW 10 mg FF/kg BW
∗Duodenum 22.9 ± 19.4a 39.5 ± 16.0a 52.2 ± 45.9a 285.8 ± 21.1b 60.8 ± 59.6a 255.3 ± 199.7a
(n = 6) (n = 4) (n = 6) (n = 4) (n = 5) (n = 4)
Jejunum 21.4 ± 6.2a 28.0 ± 22.8a 35.4 ± 14.8a 76.0 ± 24.6b 20.6 ± 20.4a 80.4 ± 33.0b
(n = 6) (n = 3) (n = 6) (n = 6) (n = 6) (n = 6)
Ileum 36.4 ± 19.8a 48.4 ± 31.3a 33.5 ± 39.6a 60.6 ± 43.1a 31.1 ± 20.8a 83.6 ± 51.8a
(n = 45) (n = 3) (n = 5) (n = 5) (n = 4) (n = 4)
Cecum 21.6 ± 13.5a 26.5 ± 12.5a 12.8 ± 6.3a 54.4 ± 12.9b 5.2 ± 4.0a 28.5 ± 23.0a,b
(n = 6) (n = 4) (n = 5) (n = 5) (n = 3) (n = 4)
Colon 19.5 ± 16.2a 20.1 ± 5.2a 16.1 ± 20.6a 31.5 ± 10.1a 13.3 ± 15.0a 11.8 ± 3.8a
(n = 4) (n = 4) (n = 4) (n = 3) (n = 3) (n = 5)
With daily oral bolus administered in group 1 and 2 during 5 days. Groups 3 and 4 were administered two IM injections with 48 h-interval and groups 5 and 6 received
medicated feed once daily during 5 days. Mean ± SD intestinal FF concentrations are displayed for the different segments. A difference in superscripts a, b denotes
a statistical significant difference between these groups. Statistics were exerted using single-factor ANOVA with post-hoc testing (Tukey or Games-Howell∗ in case of
unequal variances) and significance level p = 0.05.
FIGURE 2 | Water content calculated after a 48 h freeze-drying process of the
intestinal content samples from all treatment groups. With the oral bolus
groups 1 and 2 administered 5 and 10 mg FF/kg BW, respectively, groups 3
and 4 administered IM 15 and 30 mg FF/kg BW, respectively and groups 5
and 6 administered medicated feed at 5 and 10 mg FF/kg BW, respectively.
Water content was calculated based on the sample weight pre- and
post-freeze-drying. ∗Significant differences were detected between group 4
and group 1 (p = 0.030) after single-factor ANOVA with a post-hoc Tukey test
(equal variances). No significant differences were detected for each of the
other gastro-intestinal segments after a single-factor ANOVA with a post-hoc
Tukey test (equal variances) or in case of the rectum segment a post-hoc
Games-Howell test (equal variances not assumed), with significance level
p = 0.05 for all tests.
the gastro-intestinal tract. There is a dose-related influence, albeit
not always statistically significant, with higher concentrations
measured after administration of higher doses.
FF concentrations in fecal samples were below the LOQ
of 0.125 µg/g in all treatment groups. However, transitional
diarrhea, a well-known side effect of FF in pigs, could
potentially contribute to dilution of the samples yielding low
fecal concentrations. The exact cause of this adverse effect is
not known; although it is commonly hypothesized these effects
are due to the irritable properties of the molecule, its bacterial
killing properties causing the release of endotoxins or a shift
in microbiota during therapy (i.e., microbial dysbiosis). For the
latter it has been demonstrated in mice that an antimicrobial-
induced dysbiosis is related to an impaired gastro-intestinal
motility and an increase in fecal water content (Caputi et al.,
2017). In the present study, pigs in all treatment groups developed
diarrhea. The extent of diarrhea was estimated by comparing the
weight loss from the intestinal and fecal samples pre- and post-
freeze-drying (Figure 2). Normally, resorption of water is one
of the main functions of the distal gastro-intestinal segments,
which results in less water content. However, in this study the
water content was highest in the cecum and colon segments in
all treatment groups. After post-hoc comparison of the different
groups, significant differences were detected (p > 0.05) in water
content within the same intestinal segment; in group 4 (30 mg
FF/kg BW) the colon segment showed significantly higher mean
(n = 6) water content in comparison with group 1 (p = 0.030).
In the other intestinal segments, significant differences were not
detected.
In conclusion, this transient side-effect occurred during all
treatment strategies applied in our experimental setup, meaning
after 2 FF IM injections or after 5 days of one daily oral bolus or
medicated feed administration, although a higher water content
was observed for group 4 after IM administration of 30 mg FF/kg
BW in cecum, colon and rectum.
Microbiological Experiments and
Intestinal Florfenicol Pharmacokinetics
The microbiological analysis of the fecal samples revealed
a mean E. coli colony forming unit (CFU) count of
3.08 × 105 ± 1.99 × 105 per g faeces over the different
treatment groups at time point 0 h (Supplementary Table C).
At this time point, the vast majority of the isolates (99.5%
up to 100%) were unable to grow on the FF supplemented
MacConkey agar plates (16 µg FF/mL). Moreover, all identified
isolates (3 colonies per plate) retained from the un-supplemented
MacConkey agar had FF MIC values ranging between 2 and
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FIGURE 3 | Intestinal content concentrations of florfenicol (FF) in different gastro-intestinal segments: duodenum, jejunum, ileum, cecum and colon at 10 h after the
last administration, combined with minimal inhibitory concentration (MIC) values for susceptible and resistant Escherichia coli isolates. Results are presented as
mean + SD (n = 6). (A) Group 1 (5 mg FF/kg BW) and 2 (10 mg FF/kg BW) administered an oral bolus of florfenicol (FF) during 5 days (once daily), (B) Group 3
(15 mg FF/kg BW) and group 4 (30 mg FF/kg BW) administered intramuscular FF injections twice (48 h interval), and (C) Group 5 (5 mg FF/kg BW) and 6 (10 mg
FF/kg BW) administered medicated feed once daily during 5 days.
16 µg/mL, while the isolates retrieved from MacConkey agar
plates supplemented with FF (n = 3 colonies), all showed MIC
values of≥ 256 µg/mL (gradient test strip upper limit). However,
at the end of the treatment period (58 h for IM groups, 106 h for
oral groups), a clear shift was observed. While the total E. coli
count on plain MacConkey hardly changed after treatment,
with mean counts over the different treatment groups of 6.78
105 ± 2.00 105 CFU/g, these populations consisted mainly
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FIGURE 4 | Repetitive element sequenced-based (rep)-PCR of 42 different retrieved Escherichia coli isolates (time point 0 h and also 58 h for intramuscular treated
groups or 106 h for oral treated groups), from 6 different treatment groups and in total from 18 different pigs. The minimal inhibitory concentration (MIC in µg/mL)
was determined for each isolate. With treatment group 1 and 2 administered an oral bolus at 5 and 10 mg florfenicol (FF)/kg BW, respectively, group 3 and 4
administered FF intramuscularly twice with 48-h interval at 15 and 30 mg FF/kg BW, respectively, and group 5 and 6 administered medicated feed at 5 and 10 mg
FF/kg BW, respectively. Different genotypic groups or single isolates were found as indicated by the color scheme. The different groups are outlined between the
black lines. Genotypic diversity occurred on group- and animal-level, hence excluding selection of one resistant mutant.
of isolates (from 86.8 up to 100.0%) able to grow on the FF
supplemented MacConkey agar plates (Supplementary Table C).
All isolates retrieved at time point 58 h or 106 h showed MIC
values of ≥ 256 µg/mL. All randomly selected and purified
colonies were confirmed as E. coli by MALDI-TOF MS analysis,
with score values of ≥2.300.
The bacteriological findings were subsequently combined
with the PK data from the gastro-intestinal segments of the
individual animals. Given the time-dependent (Watteyn et al.,
2015) bacteriostatic effect of FF, the associated PK/PD index for
efficacy is time above MIC in a 24 h dosing interval (T > MIC).
However, because of the manner of intestinal sample collection,
following euthanasia, a time-dependent gut concentration profile
cannot be established over the whole course of therapy in this
study. Hence, the intestinal concentrations measured in the
different groups were matched with the wild-type MIC cut-
off for susceptible isolates (16 µg/mL) and the gradient test
strip upper limit for resistant isolates (256 µg/mL), as given
in Figure 3. Data based on the PK/PD integration, complete
eradication of susceptible E. coli strains in the different gastro-
intestinal segments is predicted by the end of therapy, which was
also reflected by the lack of susceptible isolates recovered from
the fecal samples at the end of therapy. Furthermore, all resistant
isolates retrieved at time 0 h and 58 h (end IM treatment) or 106 h
(end oral treatment) displayed MIC values of at least 256 µg/mL,
which is higher (apart from group 4) than the mean measured
maximal FF concentrations ± SD (group 1: 36.4 ± 19.8 µg/g,
group 2: 48.4 ± 31.3 µg/g, group 3: 52.2 ± 45.9 µg/g, group
4: 285.8 ± 21.1 µg/g, group 5: 60.8 ± 59.6 µg/g, group 6:
255.3 ± 199.7 µg/g), favoring selection of resistant isolates in all
treatment regimens under FF pressure.
Based on earlier literature reports, FF resistance in E. coli
is associated with values of 16 < MIC ≤ 512 µg/mL (White
et al., 2000; Bischoff et al., 2002). Furthermore, the dissemination
of FF resistance is mostly related to mobile genetic elements;
with reports of different conjugative plasmids or transposons
harboring FF resistance genes, which can be found in E. coli
field strains (Doublet et al., 2005; Meunier et al., 2010). Hence,
conjugative plasmids could contribute to the distribution of
FF resistance genes in several bacterial species and in different
animals (Cloeckaert et al., 2000; Kehrenberg et al., 2006).
FF resistance can also be located on the chromosome or
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non-conjugative plasmids (Singer et al., 2004), which would still
allow for selection of these resistant mutants under antimicrobial
pressure. In our study, before and after treatment, multiple E. coli
genotypes were detected in both the susceptible and resistant
E. coli isolates (Figure 4). There was no obvious selection toward
one or a limited number of genotypes after treatment, since the
number of resistant genotypes seemed to increase after treatment.
Even though the currently used methods cannot provide definite
proof, the obtained results suggest that both selection of pre-
existing resistant isolates and the horizontal transfer of resistance
determinants toward originally susceptible strains may have
contributed to the emergence of the resistant E. coli population,
after treatment in this experimental setup. Finally, these findings
were not related to an untreated control group. Hence, the spread
of resistant genotypes from one treatment group to another
cannot be excluded either.
Finally, in these experiments no effect of dose alteration or
administration route on resistance selection in E. coli, as Gram-
negative indicator bacterium, was observed. Even though the
animals of group 4, administered the highest IM dose of 30 mg
FF/kg BW, displayed elevated intestinal FF concentrations. In
this sense, all microbiological experiments indicated a strong
selection of resistant E. coli strains during treatment with FF,
in all treatment groups. This may be related to the fact that
all treatment strategies led to sufficiently high gastro-intestinal
concentrations for eradication of susceptible strains and allowing
for selective enrichment of resistant isolates.
CONCLUSION
In general, a linear relationship between dose and FF plasma
concentration was found for a given administration route.
Following, no significant effects of the administration route on
gastro-intestinal concentrations of FF were observed. However,
in most gastro-intestinal segments, elevated FF concentrations
were measured after IM administration of the highest dose, i.e.,
30 mg FF/kg BW. No significant differences in FF intestinal
concentrations were detected among the other treatment groups.
Bacteriological analysis of the fecal samples demonstrated the
presence of both FF susceptible and FF resistant E. coli isolates
at the start of the treatment. The susceptible isolates displayed
MIC values of 2–16 µg/mL. In relation to the high FF intestinal
concentrations measured at 10 h after the last administration,
eradication of susceptible E. coli strains is expected during
treatment. All characterized resistant isolates displayed MIC
values equal to or greater than 256 µg/mL. Hence, these high
MIC values associated with FF resistance allowed for selection of
resistance in the different gastro-intestinal segments, irrespective
of treatment group.
These results are a cause for concern in terms for gastro-
intestinal exposure of the microbiota to FF. Taking into account
that the gut microbiota is a major resistance reservoir; exposure to
such concentrations of FF could increase resistance selection and
spread, as observed in the present study for E. coli. Furthermore,
plasmid-mediated co-selection or cross resistance with FF also
has to be contemplated. FF is used for respiratory tract infections,
hence the effects of the molecule on the microbiota could be
considered as an adverse event in terms of AMR. However,
awareness of this adverse event needs to be implemented, in order
to warrant a prudent use of FF in respiratory tract infections
and minimize the risk of AMR selection and spread from the
microbiota.
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